Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

81.56 -2.44 (-2.90%)
Streaming Delayed Price Updated: 10:15 AM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,112,771
Open 82.36
Bid (Size) 81.53 (3)
Ask (Size) 81.56 (1)
Prev. Close 84.00
Today's Range 80.60 - 82.50
52wk Range 57.16 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
Mount Gilead, OH Author Publishes Children's Book
This Kids Book Features the Cutest Baby Elephant You Will Ever See! 
Via PR Leap

Performance

YTD
-4.49%
-4.49%
1 Month
-4.49%
-4.49%
3 Month
+4.73%
+4.73%
6 Month
+30.98%
+30.98%
1 Year
+19.12%
+19.12%

More News

Read More
Earnings Outlook For Gilead Sciences
Via Benzinga
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today
Via Benzinga
Could Gilead Sciences Stock Help You Become a Millionaire?
Via The Motley Fool
16 Analysts Have This to Say About Gilead Sciences
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts
Via Benzinga
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc. and Arcellx, Inc.
Via Business Wire
Mount Gilead, NC Author Publishes Children's Book
Via PR Leap
If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today
Via Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Mergers and Acquisitions in 2023 Off To A Strong Start
Via MarketBeat
Exposures Product Safety
3 Smart Stocks to Buy if a Recession Is on the Way
Via The Motley Fool
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
From Gilead Sciences, Inc.
Via Business Wire
3 Stocks That Beat the S&P During the Great Recession
Via The Motley Fool
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Via SBWire
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
2 Unstoppable Stocks That Could Beat the Market Again In 2023
Via The Motley Fool
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Via Investor's Business Daily
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
From Gilead Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.